Presentation
610 Baseline Structural Damage Predicts Response to Abatacept in Patients with Psoriatic Arthritis: A Post Hoc Analysis from a Phase III Study. American College of Rheumatology (ACR) Annual Meeting, San Diego CA, Nov. 2017. Arthritis Rheumatol 2017.
American College of Rheumatology (ACR) Annual Meeting
(2017)
Abstract
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease in which treatment selection and patient stratification based on clinical domains have recently been proposed.1 The efficacy and safety of the co-stimulation modulator abatacept in patients with PsA was investigated in the Phase III ASTRAEA study (NCT01860976).2 The aim of this analysis was to identify baseline factors that predict response to abatacept treatment in patients with PsA in ASTRAEA. Methods: Baseline disease and demographic characteristics of patients treated with abatacept (n=213) or placebo (n=211) in the Phase III ASTRAEA study achieving high-level response (ACR50: abatacept n=41, placebo n=26; ACR70: abatacept n=22, placebo n=14) at Day 169 (Week 24) were compared with those of patients not achieving an ACR20 response (abatacept n=129, placebo n=164). Due to the inclusion of an early escape (EE) at Day 114 (Week 16), patients who entered the EE were imputed as non-responders at Day 169 and included in the ACR20 non-responders group. Results:
Disciplines
Publication Date
September, 2017
Citation Information
Georg Schett, T Lehman, H Ahmad, A Johnsen, et al.. "610 Baseline Structural Damage Predicts Response to Abatacept in Patients with Psoriatic Arthritis: A Post Hoc Analysis from a Phase III Study. American College of Rheumatology (ACR) Annual Meeting, San Diego CA, Nov. 2017. Arthritis Rheumatol 2017." American College of Rheumatology (ACR) Annual Meeting (2017) Available at: http://works.bepress.com/philip-mease/163/